Trial · NCT02787083
A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis
NCT02787083, Phase 3, Terminated, Philadelphia Urosurgical Associates; results first posted 2019-12-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis. Trials, record NCT02787083. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02787083
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis
- NCT number
- NCT02787083
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 9 participants, actual
- Lead sponsor
- Philadelphia Urosurgical Associates
- Conditions
- Cystitis, Interstitial
- Interventions
- Mirabegron, Placebo
- First posted
- 2016-06-01
- Last updated
- 2019-12-03
- Results first posted
- 2019-12-03
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Interstitial Cystitis Symptom Improvement | 12 weeks | Evaluate urinary urgency, frequency and pain via validated O'Leary Sant questionnaire |
| Secondary | Number of Participants With Improvement in Incontinence Episodes | 12 weeks | Evaluate incontinence episodes via bladder diary and UDI-6 questionnaire |
| Secondary | Impact on Quality of Life | 12 weeks | Evaluate impact on quality of life from bladder, bowel and vaginal/pelvic symptoms via PFIQ-7 questionnaire |
| Secondary | Patient Satisfaction | 12 weeks | evaluate participant satisfaction with treatment/placebo via Global response assessment form |
| Secondary | Sexual Function | 12 weeks | Evaluate changes in sexual function via FSFI questionnaire |
| Secondary | Side Effects of Medication | 12 weeks | Will assess if participants have side effects of medication via office visits |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Interstitial Cystitis Symptom Improvement | 12 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With Improvement in Incontinence Episodes | 12 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Impact on Quality of Life | 12 weeks | |||
| SECONDARY | Patient Satisfaction | 12 weeks | |||
| SECONDARY | Sexual Function | 12 weeks | |||
| SECONDARY | Side Effects of Medication | 12 weeks |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Interstitial Cystitis Symptom Improvement | Mirabegron | 1 | Participants | ||
| Number of Participants With Interstitial Cystitis Symptom Improvement | Placebo | 3 | Participants | ||
| Number of Participants With Improvement in Incontinence Episodes | Mirabegron | 1 | Participants | ||
| Number of Participants With Improvement in Incontinence Episodes | Placebo | 3 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Mirabegron | 4 | |
| Overall Study | STARTED | Placebo | 5 | |
| Overall Study | COMPLETED | Mirabegron | 1 | |
| Overall Study | COMPLETED | Placebo | 3 | |
| Overall Study | NOT COMPLETED | Mirabegron | 3 | |
| Overall Study | NOT COMPLETED | Placebo | 2 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Cardiac disorders | Mirabegron | 1 | 4 | 1 |
| other | Headache | Cardiac disorders | Placebo | 0 | 5 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Mirabegron | 0 | 4 |
| Total, all-cause mortality | Placebo | 0 | 5 |
| Total, other adverse events | Mirabegron | 1 | 4 |
| Total, other adverse events | Placebo | 0 | 5 |
| Total, serious adverse events | Mirabegron | 0 | 4 |
| Total, serious adverse events | Placebo | 0 | 5 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32734597 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Mirabegron vs Placebo: Number of Participants With Improvement in Incontinence Episodes | Trial comparisons |
| Mirabegron vs Placebo: Number of Participants With Interstitial Cystitis Symptom Improvement | Trial comparisons |
| Mirabegron vs Placebo: deaths from any cause | Trial comparisons |
| Mirabegron vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02787083
GET https://conductscience.org/api/trials/v1/NCT02787083/registered